 |
 |

Early-Onset Cyclophosphamide-Induced Interstitial Pneumonitis
Jesse I. Spector, MD;
Harvey Zimbler, MD;
Jeffrey S. Ross, MD
JAMA. 1979;242(26):2852-2854.
Abstract
This article describes three cases of biopsy-proved interstitial pneumonitis secondary to cyclophosphamide therapy. The pulmonary reactions developed after one to three courses of combination chemotherapy in three patients with diffuse histiocytic lymphoma. Resolution of the pulmonary infiltrates and blood gas value abnormalities followed discontinuation of use of this drug without recurrence when chemotherapy regimens excluding cyclophosphamide were subsequently used. Prednisone was given to all patients after the diagnosis was made, but its role in the resolution of the toxic changes is uncertain. The potential for early onset of cyclophosphamide-induced interstitial pneumonitis has not been previously stressed, but should lead to vigorous investigation of pulmonary reactions occurring at any time after initiation of therapy with this drug.
(JAMA 242:2852-2854, 1979)
Author Affiliations
From the Section of Hematology-Oncology, Department of Medicine (Drs Spector and Zimbler), and the Department of Pathology (Dr Ross), Berkshire Medical Center, Pittsfield, Mass.
Footnotes
Reprint requests to Berkshire Medical Center, 725 North St, Pittsfield, MA 01201 (Dr Spector).
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Immunomodulatory and Protective Effects of Moxifloxacin against Candida albicans-Induced Bronchopneumonia in Mice Injected with Cyclophosphamide
Shalit et al.
Antimicrob. Agents Chemother. 2002;46:2442-2449.
ABSTRACT
| FULL TEXT
Cyclophosphamide stimulates lung fibroblasts to release neutrophil and monocyte chemoattractants
Koyama et al.
Am. J. Physiol. Lung Cell. Mol. Physiol. 2001;280:L1203-L1211.
ABSTRACT
| FULL TEXT
Pulmonary Drug Toxicity: Radiologic and Pathologic Manifestations
Rossi et al.
RadioGraphics 2000;20:1245-1259.
ABSTRACT
| FULL TEXT
Pulmonary Toxicity of Antineoplastic Drugs
Batist and Andrews
JAMA 1981;246:1449-1453.
ABSTRACT
|